Used in cancer immunotherapy to block the CD73 enzyme, which plays a role in suppressing the immune response within the tumor microenvironment. By inhibiting CD73, this antibody helps restore anti-tumor T cell activity, enhancing the body's ability to fight cancer. It is being investigated in clinical trials for solid tumors, often in combination with other immunotherapies like PD-1/PD-L1 inhibitors. Shows promise in cancers where CD73 is overexpressed, such as breast, ovarian, and non-small cell lung cancer.